BZ
Therapeutic Areas
Aucta Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Motpoly XR™ | Epilepsy | Not Specified (Likely Phase 3/NDA) |
| CNS Pipeline Candidates | Central Nervous System Disorders | Not Specified |
| Orphan/Specialty Pipeline Candidates | Orphan and Specialty Indications | Not Specified |
| Metabolic Disease Candidates | Metabolic Diseases | Not Specified |
| Ophthalmics Candidates | Ophthalmics | Not Specified |
| Dermatology Candidates | Dermatology | Not Specified |
| Pediatrics Candidates | Pediatrics | Not Specified |
Leadership Team at Aucta Pharmaceuticals
SL
Shoufeng Li, Ph.D.
Chief Executive Officer, Founder, Scientist
QR
Qiaolin Ren, Ph.D.
Vice President
LL
Lisheng Lu
Executive Director and Vice President of Manufacture (China)
RL
Rong Li, Ph.D.
Scientific Advisor
CJ
Chris Jarman
Vice President, Managed Markets and Operations
CL
Changjun Liu
Vice President, Quality Management
LG
Lixin Gong
Head of Analysis